2012 Fiscal Year Final Research Report
Biosynthesis of heparin proteoglycan (serglycin)
Project/Area Number |
23659108
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
General physiology
|
Research Institution | Tokyo Medical and Dental University |
Principal Investigator |
YANAGISHITA Masaki 東京医科歯科大学, 大学院・医歯学総合研究科, 教授 (70132793)
|
Co-Investigator(Kenkyū-buntansha) |
KATARZYNA ANNA Podyma-Inoue (90302877)
|
Project Period (FY) |
2011 – 2012
|
Keywords | 血液凝固 / レオロジー |
Research Abstract |
Heparin is a biological product having anticoagulant activity. It is widely used in heart-lung surgeries, hemodialysis, and in the treatment of arterial/venous thromboses. Biosynthetic processes involved in the processing of heparin, especially that of carbohydrate chains after completion in Golgi until the storage of the final products in secretion granules, have not been elucidated. The current research attempted to analyze this processes in detail, and has reached a conclusion that the “heparanase” is the key enzyme in this process and the newly generated non-reducing ends of heparin chains weresuggested to have specific functions.
|
Research Products
(19 results)
-
-
[Journal Article]2013
Author(s)
Miki Hara-Yokoyama, Kazue Terasawa, Shizuko Ichinose, Akihiko Watanabe, Katarzyna A. Podyma-Inoue, Kazunari Akiyoshi, Yasuyuki Igarashi and Masaki Yanagishita
-
Journal Title
Bioorganic & Madicinal Chemistry letter
Volume: (in press)
-
[Journal Article]2012
Author(s)
Miki Hara-Yokoyama, Mutsuko Kukimoto-Niino, Kazue Terasawa, Satoru Harumiya, Katarzyna A. Podyma-Inoue, Nobumasa Hino, Kensaku Sakamoto, Satsuki Itoh, Noritaka Hashii, Yoko Hiruta, Nana Kawasaki, Chiemi Mishima- Tsumagari, Yoko Kaitsu, Tomoko Matsumoto, Motoaki Wakiyama, Mikako Shirouzu, Takeshi Kasama, Hiroshi Takayanagi, Nakako Utsunomiya-Tate, Kiyoshi Takatsu, Toshiaki Katada, Yoshio Hirabayashi, Shigeyuki Yokoyama and Masaki Yanagishita
-
Journal Title
Structure
Volume: 20
Pages: 1585-1595
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-